Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast CancerMatthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Decreasing the flexibility of the TELSAM-target protein linker and omitting the cleavable fusion tag improves crystal order and diffraction limitsParag L Gajjar, Maria J Pedroza Romo, Celeste M Litchfield, et al.
Plos One|June 14, 2012
Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cellsLacey M Litchfield, Krista A Riggs, Alyson M Hockenberry, et al.
Oncotarget|May 12, 2020
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cellsLacey M Litchfield, Karsten Boehnke, Manisha Brahmachary, et al.
Frontiers in Oncology|February 28, 2022
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b StudySara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH TrialKevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, et al.
Cell Reports|March 15, 2018
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint BlockadeDavid A Schaer, Richard P Beckmann, Jack A Dempsey, et al.
Cancer Cell|December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor AbemaciclibXueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2021
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast CancerCarmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, et al.
Cancer Discovery|May 15, 2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast CancerSeth A Wander, Ofir Cohen, Xueqian Gong, et al.
Pageof 7